Ron Wald


Scientist, Li Ka Shing Knowledge Institute

Tel: 416-867-3703
Twitter: @DrRonWald


Ron Wald is a nephrologist and Associate Professor of Medicine at the University of Toronto. A native of Montreal, he completed his undergraduate and medical degrees at McGill University and continued his clinical training in internal medicine and nephrology at the University of Toronto. Following this, he completed a Master in Public Health at Harvard University and a research fellowship at Tufts Medical Center in Boston. Since joining the St. Michael’s Hospital Division of Nephrology in 2006, Dr. Wald has been responsible for the hospital’s acute dialysis program. In addition to attending on the hospital’s Nephrology consult and ward services, he provides longitudinal care for patients on chronic hemodialysis and has an active general nephrology practice.

Dr. Wald’s research interests are in the areas of critical care nephrology and chronic dialysis. He is currently leading a Canadian Institutes of Health Research-funded international trial on the impact of the timing of dialysis initiation on survival in critically ill patients with acute kidney injury. He also has a strong interest in the long-term outcomes of patients who survive an episode of acute kidney injury and is co-leading a trial that is comparing specialized nephrology care vs usual care in this population. In the chronic dialysis area, Dr. Wald co-led a CIHR-funded study on the cardiovascular benefits of incentre nocturnal hemodialysis. He recently completed a multicentre pilot trial examining the implementation of two different levels of serum phosphate control in the hemodialysis population. A larger definitive trial to evaluate whether intensive serum phosphate lowering mediates improved clinical outcomes is planned. As a founding member of the Kidney Dialysis and Transplantation Program of the Institute for Clinical Evaluative Sciences, Dr. Wald is also involved in several studies that are using province-wide administrative data to answer research questions in kidney disease.

Please note: Dr. Wald is not taking any summer students.

Recent Publications

  1. Sanfilippo, AJ, Kolos, A, Chan, K, Leong-Poi, H, Sasson, Z, Wald, R et al.. Impact of a Mandated Accreditation Process on 1,045 Registered Echocardiographic Service Providers in a Previously Unregulated, Publicly Funded Environment. J Am Soc Echocardiogr. 2020; :. doi: 10.1016/j.echo.2020.09.018. PubMed PMID:33191003 .
  2. Abbasi Bavil, E, Doyle, MG, Debbaut, C, Wald, RM, Mertens, L, Forbes, TL et al.. Calibration of an Electrical Analog Model of Liver Hemodynamics in Fontan Patients. J Biomech Eng. 2020; :. doi: 10.1115/1.4049075. PubMed PMID:33170219 .
  3. Wald, R, Bagshaw, SM. COVID-19-Associated Acute Kidney Injury: Learning from the First Wave. J Am Soc Nephrol. 2020; :. doi: 10.1681/ASN.2020101401. PubMed PMID:33115918 .
  4. Kawada, S, Chakraborty, P, Roche, L, Oechslin, EN, Silversides, C, Wald, RM et al.. Role of amiodarone in the management of atrial arrhythmias in adult Fontan patients. Heart. 2020; :. doi: 10.1136/heartjnl-2020-317378. PubMed PMID:33115764 .
  5. Wald, R, Bagshaw, SM, STARRT-AKI Investigators. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. Reply. N Engl J Med. 2020;383 (18):1797-1798. doi: 10.1056/NEJMc2027489. PubMed PMID:33113308 .
  6. Manshaei, R, Merico, D, Reuter, MS, Engchuan, W, Mojarad, BA, Chaturvedi, R et al.. Genes and Pathways Implicated in Tetralogy of Fallot Revealed by Ultra-Rare Variant Burden Analysis in 231 Genome Sequences. Front Genet. 2020;11 :957. doi: 10.3389/fgene.2020.00957. PubMed PMID:33110418 PubMed Central PMC7522597.
  7. Siew, ED, Liu, KD, Bonn, J, Chinchilli, V, Dember, LM, Girard, TD et al.. Improving Care for Patients after Hospitalization with AKI. J Am Soc Nephrol. 2020;31 (10):2237-2241. doi: 10.1681/ASN.2020040397. PubMed PMID:32912935 PubMed Central PMC7609013.
  8. Huang, F, Connelly, PW, Prasad, GVR, Nash, MM, Gunaratnam, L, Deva, DP et al.. Evaluation of left atrial remodeling in kidney transplant patients using cardiac magnetic resonance imaging. J Nephrol. 2020; :. doi: 10.1007/s40620-020-00853-7. PubMed PMID:32910428 .
  9. Clark, EG, Hiremath, S, McIntyre, L, Wald, R, Hundemer, GL, Joannidis, M et al.. Haemoperfusion should only be used for COVID-19 in the context of randomized trials. Nat Rev Nephrol. 2020;16 (12):697-699. doi: 10.1038/s41581-020-00352-9. PubMed PMID:32901129 PubMed Central PMC7478103.
  10. Meraz-Muñoz, A, Wald, R. Contrast-Associated Acute Kidney Injury: Will Clarifying Mechanisms Allay Anxiety?. Clin J Am Soc Nephrol. 2020;15 (9):1225-1227. doi: 10.2215/CJN.11960720. PubMed PMID:32841155 PubMed Central PMC7480549.
Search PubMed

Affiliations & Other Activities

  • Nephrologist, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto